Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
7 Results for "
OCI-Ly1 cells
" in MedChemExpress (MCE) Product Catalog:
Products (7)
7 Results for "OCI-Ly1 cells" in MCE Product Catalog:
1
1 Cited Publications
Research Areas:
MDH1-IN-2 (Compound 7c) is a selective MDH1 inhibitor, with IC50 values of 2.27 and 27.47 μM for MDH1 and MDH2, respectively. MDH1-IN-2 can reduce the generation of ROS by inhibiting the conversion of 2-Ketoglutaric acid (HY-W013636) to α-Hydroxyglutaric acid (HY-113038B) mediated by MDH1, thereby suppressing 2-Ketoglutaric acid (HY-W013636)-induced ferroptosis .
Cat. No.: HY-122829
CAS No.: 2257479-54-0
BCL6 PROTAC 1 is a selective B-cell lymphoma 6 (BCL6) PROTAC. BCL6 PROTAC 1 inhibits BCL6 cell reporter with an IC50 value of 8.8 µM. BCL6 PROTAC 1 significantly degrades BCL6 in diffuse large B-cell lymphoma (DLBCL) cell lines. BCL6 PROTAC 1 can be used in tumor related research .
Cat. No.: HY-178777
CAS No.: 3084696-50-1
BCL6-760 is an orally active BCL-6 PROTAC degrader with an EC50 of 0.8 nM. BCL6-760 only degrades BCL6 and has no effect on other CRBN substrates. BCL6-760 demonstrates significant efficacy in the orthotopic xenograft mouse model of OCI-LY-1 tumors. BCL6-760 can be used in the research of diffuse Large B-cell Lymphoma (DLBCL) (Pink: BCL-6 ligand (HY-179317); Blue: CRBN ligand (HY-179305); Black: Linker) .
Cat. No.: HY-178803
PROTAC BCL6 Degrader-2 is an orally active, selective BCL6 PROTAC degrader (DC50: 0.45 nM in HEK293T cells). PROTAC BCL6 Degrader-2 promotes ubiquitination and degradation of BCL6. It exhibits anticancer activity against BCL6-dependent diffuse large B-cell lymphoma. PROTAC BCL6 Degrader-2 can be used for the research of diffuse large B-cell lymphoma .
Cat. No.: HY-179075
Target:
Research Areas:
PROTAC BCL6/IKZF1/3 Degrader-1 is an orally active bifunctional PROTAC‑IMiD protein degrader that targets and degrades BCL6, IKZF1 and IKZF3. PROTAC BCL6/IKZF1/3 Degrader-1 induces ubiquitination and proteasome-mediated degradation of target proteins by recruiting E3 ubiquitin ligase, and triggers cell cycle arrest and apoptosis. PROTAC BCL6/IKZF1/3 Degrader-1 exhibits favorable anti-tumor activity in diffuse large B-cell lymphoma xenograft models. PROTAC BCL6/IKZF1/3 Degrader-1 can be used for the research of diffuse large B-cell lymphoma .
Cat. No.: HY-146184
CAS No.: 2378853-67-7
Target:
Research Areas:
CCT373567 is a non-degrading isomer of the BCL6 degrader CCT373566 (HY-146185). CCT373567 acts as a BCL6 inhibitor with an IC50 of 2.9 nM. CCT373567 exerts growth inhibitory activity against cancer cells expressing BCL6, but shows low activity against cancer cells with low BCL6 expression. CCT373567 can be used in research related to diffuse large B-cell lymphoma .
Cat. No.: HY-15957
CAS No.: 1579514-16-1
Target:
Research Areas:
FASN-IN-7 is a potent and orally active inhibitor of human Fatty Acid Synthase (FASN). FASN-IN-7 shows enzyme inhibition on full length FASN and the FASN KR domain with IC50 values of 28 and 54 nM. FASN-IN-7 effectively inhibits proliferation of multiple cancer cell types. FASN-IN-7 increases malonyl-CoA levels and decreases palmitate levels in tumor tissues .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
